News
‘einevonACHT.’ – Exhibition at the NCT Heidelberg shows life with breast cancer
From November 18 2024 to January 9 2025, the National Center for Tumor Diseases (NCT) Heidelberg will be hosting the exhibition ‘einevonACHT.’ by the non-profit association das Buusenkollektiv. Photographs, plaster busts and coloured torso impressions, so-called tittie tints, illustrate the profound changes that breast cancer patients undergo as a result of their diagnosis and the often intensive treatments.
The National Center for Tumour Diseases (NCT) Heidelberg is a joint institution of the German Cancer Research Center (DKFZ), the University Hospital Heidelberg (UKHD), the Heidelberg Medical Faculty of the Heidelberg University and the Thoraxklinik Heidelberg.
The exhibition ‘einevonACHT.’ uses authentic snapshots to convey the experiences that women go through during and after breast cancer treatment. The works show scars, but also hope and joie de vivre, making it clear that dealing with breast cancer can also be characterised by community and optimism.
The exhibition is open to the public from 18 November 2024 to 9 January 2025 during opening hours from 8 a.m. to 6 p.m. The works are freely accessible on the 2nd and 3rd floors of the NCT Heidelberg.
The title ‘einevonACHT.’ (one in eight) refers to the fact that one in eight women in Germany receives a breast cancer diagnosis in the course of her life – and that more and more younger women are also falling ill. The association das Buusenkollektiv, which is behind the project, is committed to changing the way society deals with breast cancer and offering those affected a platform to share their stories and support each other.
The exhibition includes photographs from the project ‘Let Your Scars Shine’, which is inspired by the Japanese kintsugi tradition. Kintsugi repairs broken pottery using gold – in the photo project, the scars of those affected are symbolically mended with gold. This makes them special and unique, creating photos full of strength, dignity and beauty.
Another way of dealing with physical changes is the Tittie-Tints events. Here, the association enables women with breast cancer to deal with their illness in a protected, appreciative setting using art therapy and creating colourful upper body prints.
Stefan Fröhling, Managing Director at the NCT Heidelberg and Head of Translational Medical Oncology at the German Cancer Research Center (DKFZ), says: ‘The “einevonACHT.” exhibition provides insights into the lives of women facing the challenge of breast cancer. We warmly invite everyone to discover the works and take a look at life with and after breast cancer.’
das Buusenkollektiv is a non-profit organisation that works to raise public awareness of how to deal with breast cancer. With creative projects like ‘einevonACHT.’, the organisation raises awareness of the challenges faced by those affected and the courage they show, and supports dialogue and community.
Rhea Seehaus, chair of the Buusenkollektiv association, says: ‘Our goal is to give the topic of breast cancer a platform, to give it a face and to raise awareness that cancer can affect anyone, including young people.’ ‘einevonACHT’ is intended as a tribute to the courage, individual beauty and fighting spirit of all those affected. We want to use it to set an example of more mindfulness, self-love and solidarity in dealing with breast cancer.’
Information at a glance
Exhibition: ‘einevonACHT.’, a project of the association dasBuensenkollektiv e.V., www.dasbuusenkollektiv.de
Duration: November 18 2024 to January 9 2025
Location: NCT Heidelberg, INF 460, 60120 Heidelberg, Gallery on the 2nd and 3rd floor
Opening hours: Monday to Friday, 8 a.m. to 6 p.m.
Admission: free
A picture for the press release is available free of charge on the internet at:
Terms of use for images relating to press releases
Use is free of charge. The NCT Heidelberg permits one-time use in connection with reporting on the subject of the press release. Please credit the copyright ‘dasBuusenkollektiv e.V.’. The image material may only be passed on to third parties after prior consultation with NCT Communications (phone: +49 6221 42-1755, email: martin.staiger(at)nct-heidelberg.de). Use for commercial purposes is prohibited.
Contact for the press:
Dr. Martin Staiger
National Center for Tumor Diseases (NCT) Heidelberg
Communication and Events
Im Neuenheimer Feld 460
69120 Heidelberg
Phone: +49 6221 42-1755
E-mail: martin.staiger(at)nct-heidelberg.de
www.nct-heidelberg.de
Dr. Sibylle Kohlstädt
German Cancer Research Center (DKFZ)
Strategic Communication and Public Relations
Im Neuenheimer Feld 280
69120 Heidelberg
Phone: +49 6221 42-2843
Fax: +49 6221 42-2968
E-mail: s.kohlstaedt@dkfz.de
www.dkfz.de
Dr. Stefanie Seltmann
Heidelberg University Hospital and Medical Faculty of Heidelberg University
Press and Public Relations
Im Neuenheimer Feld 672
69120 Heidelberg
Phone: +49 6221 56-5052
Fax: +49 6221 56-4544
E-mail: stefanie.seltmann(at)med.uni-heidelberg.de
www.klinikum.uni-heidelberg.de
The National Center for Tumor Diseases (NCT) Heidelberg
The National Center for Tumor Diseases (NCT) Heidelberg is a joint institution of the German Cancer Research Center (DKFZ), the University Hospital Heidelberg (UKHD), the Heidelberg Medical Faculty of the Heidelberg University and the Thoraxklinik Heidelberg. The aim of the NCT Heidelberg is to transfer promising approaches from cancer research into clinical practice as quickly as possible, and thus to benefit patients. This applies to both diagnosis and treatment, in aftercare or prevention. Participation in clinical studies opens up access to innovative therapies. The NCT Heidelberg is thus a leader in transferring new research results from the laboratory to the clinic The NCT Heidelberg, founded in 2004, is part of the NCT with further locations in Berlin, Dresden, SouthWest (Tübingen-Stuttgart/Ulm), WERA (Würzburg, Erlangen, Regensburg, Augsburg) and West (Essen/Cologne).
German Cancer Research Center (DKFZ)
With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.
To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:
- National Center for Tumor Diseases (NCT, 6 sites)
- German Cancer Consortium (DKTK, 8 sites)
- Hopp Children's Cancer Center (KiTZ) Heidelberg
- Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
- DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
- National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.
Heidelberg University Hospital and Faculty of Medicine: Internationally Renowned Patient Care, Research and Teaching
Heidelberg University Hospital (Universitätsklinikum Heidelberg, UKHD) is one of the largest and most prestigious medical centers in Germany. The Medical Faculty of Heidelberg University (Medizinische Fakultät Heidelberg, MFHD) belongs to the internationally renowned biomedical research institutions in Europe. Both institutions have the common goal of developing new therapies and implementing them rapidly for patients. Heidelberg University Hospital and the Medical Faculty of Heidelberg University employs around 14.500 employees and is committed to providing trainings and qualifications. Every year, around 86,000 patients and more than 1.100.000 outpatient cases are treated in more than 50 clinical departments with almost 2.500 beds.
Together with the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the German Cancer Aid, the UKHD established the first National Center for Tumor Diseases (NCT) in Heidelberg. The goal is to provide care at the highest level as an oncology center of excellence and to rapidly transfer promising approaches from cancer research to the hospital. In addition, the UKHD operates in partnership with the DKFZ and the University of Heidelberg the Hopp Children’s Cancer center Heidelberg (KiTZ), a unique and nationally known therapy and research center for oncological and hematological diseases in children and adolescents.
The Heidelberg Curriculum Medicinale (HeiCuMed) is one of the top medical training programs in Germany. Currently, there are about 4.000 future physicians studying in Heidelberg.